Wyeth Sued For Off-Label Rapamune Sales

Law360, New York (May 24, 2010, 4:43 PM EDT) -- Wyeth Pharmaceuticals Inc. has been hit with an amended whistleblower complaint alleging that the company illegally marketed Rapamune — a drug used in kidney transplants — for use in other, unapproved organ transplant operations.

A second amended qui tam complaint filed Monday in the U.S. District Court for the Eastern District of Pennsylvania alleges that Wyeth, which merged with Pfizer Inc. last year, marketed the immunosuppressant drug for use in heart, lung, liver, pancreas and islet cell transplants even though the U.S. Food and Drug Administration...
To view the full article, register now.